QIAGEN Cuts 2026 Sales Outlook Amid QuantiFERON Slump and U.S. Life Sciences Caution
Event summary
- QIAGEN's Q1 2026 net sales rose 2% to $492M, but fell 1% at constant exchange rates (CER), missing its 1% CER growth outlook.
- QuantiFERON sales dropped 5% CER due to declining U.S. and Middle East immigration testing demand.
- QIAGEN revised its full-year 2026 net sales outlook to 1-2% CER growth (down from at least 5% CER).
- Adjusted diluted EPS CER of $0.54 met expectations, but full-year guidance was lowered to at least $2.43 CER (from $2.50 CER).
- Sample technologies grew 9% CER, while QIAcuity and QIAGEN Digital Insights posted double-digit and single-digit gains, respectively.
The big picture
QIAGEN’s mixed Q1 2026 results highlight the challenges of balancing portfolio growth with external headwinds, including declining QuantiFERON demand and cautious U.S. Life Sciences spending. The company’s strategic focus on Sample technologies and digital insights reflects broader industry trends toward automation and data-driven diagnostics. However, the revised full-year outlook signals potential execution risks in a volatile market environment.
What we're watching
- Demand Rebound
- Whether QuantiFERON sales can recover from the immigration testing slump in the U.S. and Middle East.
- U.S. Life Sciences
- How sustained caution among U.S. Life Sciences customers will impact QIAGEN’s growth pillars.
- Execution Risk
- The pace at which QIAGEN can deliver on its updated 2026 targets amid geopolitical uncertainty.
Related topics